SMT201600289B - Nuove immunoadesine ctla4-ig - Google Patents

Nuove immunoadesine ctla4-ig

Info

Publication number
SMT201600289B
SMT201600289B SM201600289T SM201600289T SMT201600289B SM T201600289 B SMT201600289 B SM T201600289B SM 201600289 T SM201600289 T SM 201600289T SM 201600289 T SM201600289 T SM 201600289T SM T201600289 B SMT201600289 B SM T201600289B
Authority
SM
San Marino
Prior art keywords
immunoadhesins
ctla4
new
Prior art date
Application number
SM201600289T
Other languages
English (en)
Inventor
Gregory A Lazar
Matthew J Bernett
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US30631110P priority Critical
Priority to US33480610P priority
Priority to US41230910P priority
Priority to PCT/US2011/025747 priority patent/WO2011103584A2/en
Application filed by Xencor Inc filed Critical Xencor Inc
Publication of SMT201600289B publication Critical patent/SMT201600289B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
SM201600289T 2010-02-19 2016-08-25 Nuove immunoadesine ctla4-ig SMT201600289B (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US30631110P true 2010-02-19 2010-02-19
US33480610P true 2010-05-14 2010-05-14
US41230910P true 2010-11-10 2010-11-10
PCT/US2011/025747 WO2011103584A2 (en) 2010-02-19 2011-02-22 Novel ctla4-ig immunoadhesins

Publications (1)

Publication Number Publication Date
SMT201600289B true SMT201600289B (it) 2016-11-10

Family

ID=44483626

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600289T SMT201600289B (it) 2010-02-19 2016-08-25 Nuove immunoadesine ctla4-ig

Country Status (17)

Country Link
US (5) US8329867B2 (it)
EP (2) EP2536745B1 (it)
JP (1) JP5705242B2 (it)
KR (1) KR101926663B1 (it)
CN (2) CN106432473A (it)
AU (2) AU2011217770B2 (it)
CA (1) CA2790487A1 (it)
CY (1) CY1118001T1 (it)
DK (1) DK2536745T3 (it)
ES (1) ES2586579T3 (it)
HR (1) HRP20160938T1 (it)
HU (1) HUE030100T2 (it)
LT (1) LT2536745T (it)
PL (1) PL2536745T3 (it)
SI (1) SI2536745T1 (it)
SM (1) SMT201600289B (it)
WO (1) WO2011103584A2 (it)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
KR20200023536A (ko) 2008-04-11 2020-03-04 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
PL2506871T3 (pl) 2009-11-30 2017-03-31 Janssen Biotech, Inc Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
CA2790487A1 (en) * 2010-02-19 2011-08-25 Xencor, Inc. Novel ctla4-ig immunoadhesins
TW201134481A (en) * 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
AU2012222252B2 (en) 2011-02-25 2016-08-25 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc antibody
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
KR101536151B1 (ko) * 2012-01-31 2015-07-14 서울대학교산학협력단 새로운 CTLA-4IgG 융합 단백질
US9758566B2 (en) * 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
DK3207938T3 (da) 2012-05-11 2020-03-16 Medimmune Ltd Ctla-4-varianter
WO2013181575A2 (en) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
EP2855533A4 (en) * 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc Methods related to ctla4-fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
US20150004161A1 (en) * 2013-07-01 2015-01-01 University Of Maryland Fc Coupled Compositions and Methods of Their Use
CA2924172A1 (en) * 2013-09-13 2015-03-19 Beigene, Ltd. Anti-pd1 antibodies and their use as therapeutics and diagnostics
CN110156892A (zh) 2014-07-03 2019-08-23 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
US10428146B2 (en) 2014-07-22 2019-10-01 Cb Therapeutics, Inc. Anti PD-1 antibodies
WO2016022630A1 (en) 2014-08-05 2016-02-11 Jiping Zha Anti-pd-l1 antibodies
KR20170044751A (ko) 2014-09-03 2017-04-25 베링거잉겔하임인터내쇼날유한회사 Il-23a 및 tnf-알파를 표적으로 하는 화합물 및 이의 용도
WO2016081748A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
SG11201706543UA (en) * 2015-02-20 2017-09-28 Kissei Pharmaceutical Fc Fusion High Affinity IgE Receptor α-Chain
CN107667173A (zh) 2015-05-06 2018-02-06 斯尼普技术有限公司 改变微生物种群和改善微生物群
AU2016271111A1 (en) 2015-05-29 2017-12-07 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
EA201890162A1 (ru) 2015-06-29 2018-07-31 Бристол-Маерс Сквибб Компани Антитела к cd40 с повышенной агонистической активностью
AU2016349632A1 (en) 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
EP3192805A1 (en) * 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
CA3016534A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
BR112018067368A2 (pt) 2016-03-04 2019-01-15 Squibb Bristol Myers Co terapia de combinação com anticorpos anti-cd73
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
TW201843173A (zh) 2017-04-07 2018-12-16 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
EP3630833A1 (en) 2017-05-25 2020-04-08 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2019133747A1 (en) 2017-12-27 2019-07-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
WO2019173223A1 (en) * 2018-03-05 2019-09-12 New York University Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins
WO2019185551A1 (en) 2018-03-25 2019-10-03 Snipr Biome Aps. Treating & preventing microbial infections
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
WO2020088645A1 (en) * 2018-11-02 2020-05-07 Beijing Vdjbio Co., Ltd. Modified ctla4 and methods of use thereof
WO2020106621A1 (en) 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
WO2020112781A1 (en) 2018-11-28 2020-06-04 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2020113029A2 (en) 2018-11-28 2020-06-04 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368059A1 (en) * 2001-01-26 2003-12-10 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
CA2693053A1 (en) 2007-05-30 2008-12-11 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CA2703263C (en) * 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
HUE024903T2 (en) * 2007-12-26 2016-02-29 Xencor Inc Fc variants with altered binding to fcrn
ES2458541T3 (es) 2008-05-02 2014-05-06 Seattle Genetics, Inc. Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
CA2790487A1 (en) 2010-02-19 2011-08-25 Xencor, Inc. Novel ctla4-ig immunoadhesins
TW201134481A (en) * 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses

Also Published As

Publication number Publication date
KR101926663B1 (ko) 2018-12-07
US20140112924A1 (en) 2014-04-24
HRP20160938T1 (hr) 2016-10-07
CN103038251B (zh) 2016-08-17
ES2586579T3 (es) 2016-10-17
HUE030100T2 (en) 2017-04-28
DK2536745T3 (en) 2016-08-22
CY1118001T1 (el) 2017-05-17
EP3053932B1 (en) 2020-07-22
US20190127437A1 (en) 2019-05-02
US8629113B2 (en) 2014-01-14
AU2016202816B2 (en) 2018-01-04
CA2790487A1 (en) 2011-08-25
KR20120120993A (ko) 2012-11-02
US20110287032A1 (en) 2011-11-24
US20160264643A1 (en) 2016-09-15
LT2536745T (lt) 2016-09-26
EP2536745B1 (en) 2016-05-11
CN106432473A (zh) 2017-02-22
PL2536745T3 (pl) 2017-01-31
JP5705242B2 (ja) 2015-04-22
CN103038251A (zh) 2013-04-10
SI2536745T1 (sl) 2016-10-28
JP2013520176A (ja) 2013-06-06
US8329867B2 (en) 2012-12-11
US9371397B2 (en) 2016-06-21
EP2536745A2 (en) 2012-12-26
AU2011217770A1 (en) 2012-09-06
AU2011217770B2 (en) 2016-02-04
WO2011103584A3 (en) 2012-07-12
WO2011103584A2 (en) 2011-08-25
US10155800B2 (en) 2018-12-18
EP3053932A1 (en) 2016-08-10
US20130089550A1 (en) 2013-04-11
AU2016202816A1 (en) 2016-05-26
WO2011103584A9 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
SMT201500301B (it) Saggi biologici codificati spazialmente
CO6920260A2 (es) Ambiente de aplicación múltiple
NO2019007I1 (no) Tisagenlekleucel
NO2019020I1 (no) lanadelumab
SMT201500291B (it) Nuovi agenti antimalarici
NO2019038I1 (no) Risankizumab
SMT201600293B (it) Composti chimici
NO2019022I1 (no) Natriumzirkoniumsyklosilikat
CO6811812A2 (es) Anticuerpo anti-b7-h3
NO2018039I1 (no) Rukaparibkamsylat
ITVI20100321A1 (it) Bottiglia
SMT201600289B (it) Nuove immunoadesine ctla4-ig
NO20140526A1 (no) Svanehals-ledningssystem
NO20131470A1 (no) Bropluggverktøy
NO2010019I2 (no) 6-per-deoksy-6-per-(2-karboksetyl)tio-y-cyklodextrin
NO20120395A1 (no) Stromningsstyringssystem
CR20130228A (es) Anticuerpos neutralizadores anti-ccl20
CR20130111A (es) Triazina-oxidiazoles
NO2017034I1 (no) Idarucizumab
SMT201600193B (it) Nuovo anticorpo anti-dr5
CO6960543A2 (es) 2-tiopirimidinonas
CO6801726A2 (es) Compuestos
NO20100814A1 (no) Tynnkompositter
SMT201500078B (it) Fellosilicato modificato
NO20110970A1 (no) Oppbygget flenslasedeksel